Castration-Resistant Prostate Cancer: AUA Guideline 2018

STAGING/H&P/IMAGING

Non-metastatic CRPC

Index Patient 1

STANDARD
Apalutamide or enzalutamide with continued androgen deprivation for patients at high risk for developing metastatic disease (Evidence Level Grade A)

RECOMMENDATION
Observation with continued androgen deprivation for patients at high risk for developing metastatic disease (Evidence Level Grade C)

OPTION
Second-generation androgen synthesis inhibitor (abiraterone + prednisone) to select patients at high risk for developing metastatic disease who do not want or cannot have one of the standard therapies and are unwilling to accept observation (Evidence Level Grade C)

RECOMMENDATION AGAINST
Systemic chemotherapy or immunotherapy outside the context of a clinical trial (Evidence Level Grade C)

Bone Health

RECOMMENDATION
Preventative treatment (e.g. supplemental calcium, vitamin D) for fractures and skeletal related events (Evidence Level Grade C)

OPTION
Choose either denosumab or zoledronic acid when selecting a preventative treatment for skeletal related events for mCRPC patients with bony metastases (Evidence Level Grade C)

RECOMMENDATION AGAINST
Estramustine or sipuleucel-T (Evidence Level Grade C)

STANDARD
Abiraterone + prednisone, enzalutamide, docetaxel, or sipuleucel-T (Evidence Level Grade A [abiraterone + prednisone and enzalutamide] / B [docetaxel and sipuleucel-T])

OPTION
First-generation anti-androgen therapy, ketoconazole + steroid or observation to patients who do not want or cannot have one of the standard therapies (Evidence Level Grade C)

STANDARD
Abiraterone + prednisone, enzalutamide, docetaxel, or sipuleucel-T (Evidence Level Grade A) / B (docetaxel and sipuleucel-T)

OPTION
First-generation anti-androgen therapy, ketoconazole + steroid or observation to patients who do not want or cannot have one of the standard therapies (Evidence Level Grade C)

Index Patient 2

STANDARD
Abiraterone + prednisone, enzalutamide, docetaxel, or sipuleucel-T (Evidence Level Grade A [abiraterone + prednisone and enzalutamide] / B [docetaxel and sipuleucel-T])

OPTION
First-generation anti-androgen therapy, ketoconazole + steroid or observation to patients who do not want or cannot have one of the standard therapies (Evidence Level Grade C)

Index Patient 3

STANDARD
Abiraterone + prednisone, enzalutamide, or docetaxel (Evidence Level Grade A [abiraterone + prednisone and enzalutamide] / B [docetaxel])

Radium-223 to patients with symptoms from bony metastases from mCRPC without known visceral disease (Evidence Level Grade B)

OPTION
Ketoconazole + steroid if abiraterone + prednisone, cabazitaxel or enzalutamide is unavailable (Evidence Level Grade C)

Renewal with docetaxel to patients who were benefiting at the time of discontinuation (due to reversible side effects) of docetaxel chemotherapy (Evidence Level Grade C)

Index Patient 4

STANDARD
Abiraterone + prednisone, enzalutamide, docetaxel, or sipuleucel-T (Evidence Level Grade A [abiraterone + prednisone and enzalutamide] / B [docetaxel and sipuleucel-T])

OPTION
First-generation anti-androgen therapy, ketoconazole + steroid or observation to patients who do not want or cannot have one of the standard therapies (Evidence Level Grade C)

Index Patient 5

STANDARD
Abiraterone + prednisone, cabazitaxel, or enzalutamide; if the patient received abiraterone + prednisone prior to docetaxel chemotherapy, he should be offered cabazitaxel or enzalutamide (Evidence Level Grade A [abiraterone + prednisone and enzalutamide] / B [cabazitaxel])

Radium-223 to patients with symptoms from bony metastases from mCRPC and without known visceral disease (Evidence Level Grade B)

OPTION
Ketoconazole + steroid if abiraterone + prednisone, cabazitaxel or enzalutamide is unavailable (Evidence Level Grade C)

Index Patient 6

STANDARD
Abiraterone + prednisone, enzalutamide, docetaxel, or sipuleucel-T (Evidence Level Grade A)

OPTION
Estramustine or sipuleucel-T (Evidence Level Grade C)

RECOMMENDATION AGAINST
Systemic chemotherapy or immunotherapy (Evidence Level Grade C)

RECOMMENDATION
Observation with continued androgen deprivation for patients at high risk for developing metastatic disease (Evidence Level Grade C)

RECOMMENDATION AGAINST
Sipuleucel-T (Evidence Level Grade C)

RECOMMENDATION AGAINST
Systemic chemotherapy or immunotherapy (Evidence Level Grade C)

PREVENTATIVE TREATMENT
Preventative treatment (e.g. supplemental calcium, vitamin D) for fractures and skeletal related events (Evidence Level Grade C)

OPTION
Choose either denosumab or zoledronic acid when selecting a preventative treatment for skeletal related events for mCRPC patients with bony metastases (Evidence Level Grade C)

RECOMMENDATION AGAINST
Estramustine or sipuleucel-T (Evidence Level Grade C)

RECOMMENDATION
Preventative treatment (e.g. supplemental calcium, vitamin D) for fractures and skeletal related events (Evidence Level Grade C)

OPTION
Choose either denosumab or zoledronic acid when selecting a preventative treatment for skeletal related events for mCRPC patients with bony metastases (Evidence Level Grade C)

RECOMMENDATION AGAINST
Estramustine or sipuleucel-T (Evidence Level Grade C)